Editas Medicine Inc
Open
BrancheGesundheitswesen
2.7 1.5
Übersicht
Veränderung der Aktienkurses
24h
Min
2.61
Max
2.71
Einkommen | 6.8M -18M |
|---|---|
Verkäufe | 9.1M 12M |
EPS | -0.15 |
Gewinnspanne | -153.322 |
Angestellte | 87 |
EBITDA | 3.9M -20M |
Nächstes Ergebnis | 9. Nov. 2026 |
|---|
Marktkapitalisierung | 89M 496M |
|---|---|
Vorheriger Eröffnungskurs | 1.2 |
Vorheriger Schlusskurs | 2.7 |
Nachrichtenstimmung
By Acuity
75%
25%
309 / 339 Ranking in Healthcare
Editas Medicine Inc Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Ähnliche Nachrichten
Peer-Vergleich
Kursveränderung
Editas Medicine Inc Prognose
Stimmung
By Acuity
309 / 339 Ranking in Gesundheitswesen
Nachrichtenstimmung
Sehr starke bärische Evidenz
Volatilität
Unterdurchschnittlich
Nachrichtenvolumen (RCV)
Unterdurchschnittlich
Finanzen
Vertriebs- und Verwaltungskosten
Betriebsaufwand
Gewinn vor Steuern
Verkäufe
Umsatzkosten
Bruttogewinn aus dem Verkauf
Zinsaufwand für Schulden
EBITDA
Betriebsergebnis
$
Über Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.